Opinion · Supreme Court of the United States

United States v. Coca Cola Co. of Atlanta

241 U.S. 265

Type
Opinion
Court
Supreme Court of the United States
Jurisdiction
Federal
Date
1916-05-22
Topic
general

Mr. Justice Hughes delivered the opinion of the court. This is a libel for condemnation under the Food and Drugs Act (June 30, 1906, c. 3915, 34 Stat. 768) of a certain quantity of a food product known as ‘Coca Cola’ transported, for sale, from Atlanta, Georgia, to Chattanooga, Tennessee. It was alleged that the product was adulterated and misbranded. The allegation of adulteration was, in substance, that the product contained an added poisonous or added deleterious ingredient, caffeine, *271 which might render the product injurious to health.

Citator

UpLaw has not yet analyzed United States v. Coca Cola Co. of Atlanta. The absence of a flag is not a finding that it is good law.

Cited by
38 opinions

Headnotes

  1. Healthcare Law — Adulteration — Added Ingredient Under the Food and Drugs Act of 1906, a poisonous or deleterious ingredient may be an "added" ingredient within the meaning of § 7, subdivision Fifth, even though it is covered by a proprietary formula and made a constituent of the article sold; the fact that a formula has been made up and followed and a distinctive name adopted does not take the article outside the statute, and the standard by which the combination is judged is not necessarily the combination itself. 241 U.S. at 271–272, 276–277
  2. Healthcare Law — Adulteration — Statutory Meaning The term "adulteration" in the Food and Drugs Act is used in a special sense, and its ordinary meaning is not controlling; component parts or constituents of the article are included within the definition, so that a substance may be an "added" ingredient although it is a constituent of the finished product, and an article may be adulterated by the adding of an injurious ingredient, including a component part of the article itself. 241 U.S. at 275–276
  3. Healthcare Law — Adulteration Distinguished from Misbranding Adulteration under § 7 of the Food and Drugs Act is not to be confused with misbranding; the fact that the misbranding provisions require a statement of certain substances contained in an article of food does not limit the explicit and broader provisions of § 7 as to adulteration, and both provisions remain operative. 241 U.S. at 276
  4. Healthcare Law — Proprietary Foods Proprietary foods sold under distinctive names are within the purview of § 7, subdivision Fifth, of the Food and Drugs Act; the statute contemplates that mixtures or compounds made under trade formulas and bearing distinctive names may nonetheless contain added poisonous or deleterious ingredients, and if they do the article is not saved from condemnation by its formula or name. 241 U.S. at 276–277
  5. Healthcare Law — Foods on the Market at Enactment An article of food, including a proprietary food, is not exempted from the condemnation of § 7, subdivision Fifth, of the Food and Drugs Act merely because it was already on the market when the statute was passed; the Act makes no such distinction, and neither the length of the period of traffic nor its extent affects the question if the article is in fact adulterated. 241 U.S. at 277
  6. Healthcare Law — Added Ingredient — Artificial Introduction The word "added" in § 7, subdivision Fifth, of the Food and Drugs Act refers to ingredients artificially introduced by man, whether into a natural food product or into a compound; the addition of a poisonous or deleterious ingredient having the described injurious effect causes the prohibition to attach regardless of whether the resulting mixture bears a new name or constitutes a proprietary food, and the term refers to an added ingredient, not to an added quantity of the ingredient. 241 U.S. at 280–282
  7. Healthcare Law — Adulteration — Jury Question Whether an added ingredient, such as caffeine, is poisonous or deleterious and may render an article of food injurious to health is a question of fact for the jury where the evidence is in decided conflict; the court may not direct a verdict on that issue. 241 U.S. at 282–283
  8. Healthcare Law — Misbranding — Distinctive Name Under the proviso in § 8 of the Food and Drugs Act, a "distinctive name" is a name that distinguishes; it may be a name in common use as a generic or trade description, and a name that had originally a different significance may become distinctive, but the immunity does not extend to an article offered for sale under the distinctive name of another article, and an arbitrary or fanciful name qualifies only if not already appropriated to something else so that its use would tend to deceive. 241 U.S. at 285–286
  9. Healthcare Law — Misbranding — Descriptive Names A name that is merely descriptive of ingredients is not a distinctive name within the meaning of the proviso in § 8 of the Food and Drugs Act unless it appropriately describes the compound with such ingredients; to call a compound by a name descriptive of ingredients that are not present is not to give it its own distinctive name but the name of a different compound, and the name is not protected unless it has acquired a secondary significance as the name of a product known to be destitute of the ingredients indicated by its primary meaning. 241 U.S. at 286–288
  10. Healthcare Law — Misbranding — Compound Descriptive Name A combination of descriptive names does not constitute a distinctive name within the protection of the proviso in § 8 of the Food and Drugs Act where the single names each describe an article and either or both of the described ingredients is absent, for such a combined name designates a different compound rather than distinguishing the product actually sold. 241 U.S. at 287–288